In the hope of future treatments to prevent or slow down the disease, there is a strong movement towards an ever-earlier detection of Alzheimer's disease (AD). In conjunction with scientific developments, this has prompted a reconceptualization of AD, as a slowly progressive pathological process with a long asymptomatic phase.
a number of conceptual and ethical questions. We evaluate whether these new concepts are theoretically defensible, in light of theories of health and disease, and whether they should be understood as disease or as an at-risk state. We introduce a pragmatic view on disease concepts and argue that an evaluation of the reconceptualization of AD should also take its aims and effects into account, and assess their ethical acceptability. The reconceptualization of AD is useful to coordinate research into preventive strategies, and may potentially benefit future patients. However, in the short term, early detection and labelling of 'preclinical AD' can potentially harm people. Since there is no treatment available and the predictive value is unclear, it may only create a group of 'patients-in-waiting' who may suffer from anxiety, uncertainty and stigmatization, but will never actually develop dementia. We conclude that only if the promise of preventive medication materializes, will the reconceptualization of AD turn out unequivocally to be for the better. Otherwise, the reconceptualization may do more harm than good.
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THE C A S E
A 75-year-old man visits a memory clinic because of memory complaints over the past 6 months. His wife was the first to notice. He used to have a fantastic memory, but now he sometimes forgets conversations they had. He also has a tendency to repeat a story he has told not so long ago. The couple live independently and have an active social life. The 'patient' plays tennis in a near-by village, where he travels to by car or bike, depending on the weather. They have always done the financial administration of their household together.
This has not really changed, although he has become slightly insecure and lets his wife take more decisions than he used to. On formal cognitive testing he has slight memory impairment, but no impairment in other cognitive domains such as executive functioning, language or visuospatial functioning.
This person clearly does not have dementia. In spite of some memory impairment he has almost normal and independent daily functioning. But the question is whether he is showing signs of a very early stage of a devastating brain disease that will eventually lead to dementia. Should we aim to label this person as having a disease at this point? And can we actually predict with sufficient accuracy if and when this person will eventually develop dementia? And if so, would this person benefit from this prediction?
| INTRODUC TI ON
In the hope of future treatments to prevent or slow down the disease, there is a strong movement towards an ever-earlier detection of Alzheimer's disease (AD). It is believed that brain changes presumed eventually to lead to dementia start to develop years to decades before clinical symptoms of dementia occur.
1 It seems attractive to develop treatments that can stop or slow down these changes as early as possible, even before symptoms of cognitive impairment arise. It is now possible to detect certain biomarkers -proteins in cerebrospinal fluid (CSF) and protein depositions on neuroimaging -that are presumed to reflect the early brain changes that may eventually lead to clinical dementia, in persons with no or only mild cognitive impairment. Biomarkers are thus increasingly seen as means for early detection of the disease.
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In line with these scientific developments, a reconceptualization of the notion of AD is taking place. Instead of being defined by the clinical syndrome of dementia, AD is more and more depicted as a well-defined slowly progressive pathological process with a long asymptomatic phase. A new lexicon has even been proposed and new concepts and definitions have been introduced, such as 'preclinical' and 'prodromal' AD in those with no or only mild symptoms.
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While currently mainly used in research, these new concepts of preclinical and prodromal AD, as well as the use of biomarkers that define these 'conditions', which were originally intended for research purposes, are now gradually entering clinical practice.
This reconceptualization of AD, and the concomitant emerging use of biomarkers aiming to detect biological evidence of a presumed pathological process, raise a number of conceptual and ethical questions. First, from a theoretical perspective it is questionable whether a state with abnormal biomarkers but without overt clinical symptoms should be considered as a disease, or rather as an at-risk state.
For the persons it concerns, the distinction between risk prediction and a very early diagnosis of a much-feared disease may not be that clear. This is further complicated by the fact that it is still contested how accurately biomarkers can predict future symptomatic disease.
Hence, the exact meanings of biomarker-based categorizations of preclinical and prodromal AD are unclear.
Second, from a moral perspective, the unclear predictive abilities of current biomarker tests and the current lack of meaningful treatment and prevention options -a lack of actionability -make it questionable whether the categorization of people as having an asymptomatic early phase of AD is defensible. It could create a group of 'patients in waiting' who may suffer from anxiety and fear for the future, but may never actually develop dementia. In this article we aim to address these important conceptual and ethical questions that result from the recent reconceptualization of AD. We will discuss whether the new concepts of preclinical and prodromal AD are theoretically defensible and ethically desirable and consider their implications for medical practice.
| FROM ALOIS AL ZHEIMER TO CURRENT D IS E A S E CRITERIA
Historically, the notion of AD has changed considerably since Alois
Alzheimer first described the case of Auguste D who developed 'presenile dementia' in her early fifties, in 1907. For decades, AD was considered a rare form of dementia with an onset at relatively young age. This as opposed to the common 'senile dementia', which was considered to be attributable to cerebral atherosclerosis. It was not until the 1970s that neurologist Robert Katzman first suggested that most dementia cases, also in later life, should be considered as AD.
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This led to a radical change in disease concepts and a dramatic increase in interest of the scientific world in dementia. In the 1980s the proteins of which the plaques and tangles Alois Alzheimer described consisted were identified as amyloid-β and tau, respectively.
This further enhanced research and fueled the hope for earlier diagnosis and potential treatment.
In parallel, clinical concepts started shifting, and the early disease stages, before the onset of dementia -which is defined by impairment in daily functioning -got more attention. In the late 1990s, 'mild cognitive impairment' (MCI) was introduced as an entity defined by cognitive impairment, but not severe enough to impair daily functioning. So over the last century AD seems to have changed from a rare presenile form of dementia, clinically defined and characterized by the presence of cognitive impairment leading to functional decline, of which a certain diagnosis could only be made post-mortem, to a common biologically defined condition in older people with or without cognitive impairment. The current views as represented in Table 1 illustrate the conception of AD as a slowly progressive pathophysiological process that will eventually lead to symptoms that will worsen and ultimately result in full-blown dementia. This process can presumably be detected early on (before any clinical symptoms are present) and is -also presumably -unidirectional. The often-invoked metaphor of a cascade (as in the amyloid cascade hypothesis 7 ) indicates necessary progression in a single direction: inevitable decline.
The current amyloid cascade model is, however, hypothetical.
The biological mechanisms are still insufficiently understood and it is not certain that the brain changes that define the condition do inevitably lead to symptoms. It is known that a considerable proportion of people dying in old age without cognitive impairment have a substantial load of amyloid-β and abnormal tau protein, considered to be the hallmarks of AD, in their brains. 
| AL ZHEIMER ' S D IS E A S E AND THEORIE S OF HE ALTH AND D IS E A S E
In order to consider the defensibility of the new disease concepts proposed in the AD field, we take a look at how health and disease in 9 Of course one could argue that those with Alzheimer changes without dementia simply died before they had the chance to develop symptoms and those with a clinical diagnosis of Alzheimer's dementia who did not have AD pathology were misdiagnosed during life.
Still, these data, as well as the data on MCI, cast doubt on the validity of the amyloid cascade hypothesis. However, it is not uncommon in medicine to recognize asymptomatic disease -for example asymptomatic cancer, or asymptomatic renal failure -and Nordenfelt would probably agree that these are diseases because over time they do indeed tend to reduce the ability to attain vital goals. The bigger the chance that a pathological process will lead to symptoms within a short timeframe, the more reason there is to call this 
| A PR AG MATIC APPROACH TO D IS E A S E CON CEP TS
The debate about definitions of disease in the philosophy of medicine has been focused primarily on the dispute between naturalist 
| E VALUATING THE CON CEP TS OF PRECLINIC AL AND PRODROMAL AL ZHEIMER ' S D IS E A S E
Evaluating the reconceptualization of AD in relation to scientific evidence is primarily a task for scientists, and one that is presently being taken on in the Alzheimer's research literature. we will focus on evaluating the aims, goals and effects -both intended and unintended -of the concepts of preclinical and prodromal AD, referring to a state in which there is no dementia, but abnormal biomarkers presumably related to AD are present.
| Aims and goals of the reconceptualization
The first evaluative question to be asked from a pragmatic perspec- 
| Effects of the reconceptualization on individuals
The next important evaluative question regards the effects of the reconceptualization. These can be both intended or unintendedbut sometimes foreseeable -and can manifest at either the individual or societal level.
A first concern here is what happens when the terminology that was introduced in the context of research, and intended primarily for communication between researchers, also gets employed in the clinic and in communication with research participants, patients and their family members, as is often the case. The emotional and social effects of terms chosen to communicate with lay-people can be considerable; being told one is 'at risk' for developing AD is different from being told one has preclinical or asymptomatic AD -although the situations these terms aim to describe may be exactly the same.
Likewise, being told one is in the early stages of AD is different from being told that biomarkers have been detected that may indicate that one is at increased risk of developing dementia within 10-15 years. In dealing with research participants and patients, terminology has different connotations and effects than in communication among researchers. Terms chosen should convey a truthful image of the condition of the person, and not cause confusion, unnecessary anxiety or misconceptions. 32 Giving someone a diagnosis can be understood as a 'speech act': it turns a healthy person or research participant into a patient, which has considerable psychological and social consequences and may be harmful, particularly in the case discussed here,
where the person it concerns may never develop any symptoms.
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A second concern is that defining these new conditions of 'being at risk' or having preclinical and prodromal AD -whatever the exact terms that one uses to describe them -is not necessarily in the best interest of the people involved. 
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At present, there is insufficient knowledge about the actual frequency of these potential harms and burdens and about their severity. Little is known about the psychological impact of learning one's risk status, or learning that one has 'preclinical' or 'prodromal' AD.
| Societal effects
Finally, we should consider the effects of the reconceptualization on a societal level. 40 Depending on the context and the level of public awareness, a large proportion of the elderly population may eventually prove to be 'at risk for AD' or even to have (an early stage of) AD.
Although population-based screening programmes for those over 65
do not seem very likely at this moment, other levels of screening for cognitive impairment may become reality, such as in the context of comprehensive geriatric assessments, which are increasingly popular, or opportunistic screening in those who are presumed to be at risk for cognitive impairment due to clinical or demographic characteristics.
Labelling large numbers of people as such will inevitably raise questions about medicalization of aging and age-related memory problems, since a growing number of people will be diagnosed with AD without clinical dementia or MCI being present; and without being sure whether they would ever develop it. The number of 'pa- 
| Taking stock
So, from an individual as well as societal perspective, it is questionable whether the reconceptualization of AD is desirable. Is it a good idea to distinguish, to name and to detect a condition of 'being at risk for developing AD dementia' in the first place? The answer is that it might be, in the long run, if the hypothesis on which current research efforts are based proves to be right, and if effective, safe and affordable preventive medication is developed. However, this is by no means a certainty.
For the short term, with the current state of affairs, the answer is likely to be 'no'. Detecting and labelling an uncertain condition of being at risk -although we do not exactly know how big a risk -for developing AD dementia somewhere in the future does little benefit, as long as the predictive value is unclear and there are no effective preventive measures available.
The reconceptualization is taking out a mortgage on the future success of a specific research agenda, but it may do so at the expense of current research participants, patients and older people in general. This is not necessarily unethical but we should at least be aware of it, weigh the pros and cons and minimize the negative effects. One way to do this is to be very careful with the vocabulary used to address research participants. As Alzheimer Europe states in a recent report:
'Careful attention should be paid by researchers to the terminology surrounding what is currently defined as pre-clinical AD and to its possible impact on research participants and the general public.'
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They recommend, for example, that research participants falling in the preclinical AD category, should be described as 'being at risk of AD' rather than as 'having preclinical AD', and that researchers should speak of 'disclosure of risk status', rather than of 'diagnosis'.
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Moreover, we believe clinicians who are also involved in research should be acutely aware of these issues and should take utmost care not to conflate research language with clinical language when speaking to patients. We should consider the reconceptualization and the proposed terminology and classification as research tools, not as referring to clinical 38 For example, Vanderschaeghe, G., Schaeverbeke, J., Vandenberghe, R., & Dierickx, K.
entities. The AD research community should take responsibility to prevent terms like 'preclinical AD', 'asymptomatic AD' or 'at risk for AD' from prematurely entering the consulting room and the public domain.
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| CON CLUS ION
While the reconceptualization of AD, and especially the introduction of the notion of preclinical or asymptomatic AD, might seem attractive for research into preventive strategies, and may have the potential to benefit future patients, it will not benefit individuals in the short term. It may lead to diagnosing a pre-symptomatic condition that in a considerable proportion of cases will never become symptomatic.
This can be harmful for individuals and their caregivers. It is important to consider the possible harmful effects of creating these new, uncertain and unclear conditions of pre-dementia AD in evaluating the defensibility of the proposed reconceptualization. A fundamental shortcoming in the current scientific AD debate is that illness is overlooked and that the disease is being oversimplified by characterizing it as the presence of biological abnormalities which in themselves correlate poorly with the clinical symptoms of cognitive impairment.
We conclude that the reconceptualization of AD is legitimate and meaningful for usage within a narrowly defined research community studying a clearly defined biological condition, namely the presence of specific measurable biomarkers, but that translation to clinical practice poses various ethical and communication problems. It is too early to move those concepts from research into the clinical setting, since they are based on a disputed hypothesis and since attempts to do so may actually be harmful to the people concerned. The distinction between research and clinical practice may be difficult to maintain, however, and it appears as if the use of biomarkers is slowly creeping into clinical practice, without proper scientific underpinning.
46
Whether it is a good idea to move toward ever-earlier diagnosis of AD, or of detecting at-risk states for AD dementia, is a complex question. A good predictive value and actionability are important preconditions for the ethical implementation of predictive testing. With regard to the first condition, biomarker tests for AD currently fall short, while, for the time being, the second is limited to 'preparing for one's future'.
Only if the promise of preventive medication materializes, will the reconceptualization of AD turn out to be unequivocally for the better.
However, if the attempts to develop such medication continue to fail, the reconceptualization may do more harm than good.
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